LLY vs ORCL: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
VS
Oracle Corporation · Technology
$175.08
+24.7% upside to fair value
Grade B
QuantHub Verdict
LLY has more upside to fair value
(+71.1%).
LLY trades at a lower forward P/E
(27.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
ORCL |
| Current Price |
$939.47 |
$175.08 |
| Fair Value Estimate |
$1,607.00 |
$218.26 |
| Upside to Fair Value |
+71.1%
|
+24.7%
|
| Market Cap |
$887.6B |
$503.5B |
| Forward P/E |
27.4x
|
30.8x
|
| EV / EBITDA |
35.8x
|
21.4x
|
| Price / Sales |
14.8x
|
7.9x
|
| Price / FCF |
107.6x
|
-20.4x
|
| Revenue Growth YoY |
+44.7%
|
+7.0%
|
| Gross Margin |
83.8%
|
66.4%
|
| Operating Margin |
45.6%
|
30.8%
|
| Return on Equity |
77.8%
|
57.4%
|
| Dividend Yield |
0.56% |
0% |
| FCF Yield |
0.93%
|
—
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Oracle Corporation is a leading technology company specializing in software infrastructure, with a dominant Cloud and License Business segment generating 85.8% of its $57.4 billion revenue in fiscal 2025. The company benefits from a durable competitive moat driven by decades of leadership continuity, aggressive M&A history, and a strong position in enterprise software and cloud services. Despite …
Accumulation Zones
| Metric |
LLY |
ORCL |
| Zone Low |
$1,205.00 |
$163.69 |
| Zone High |
$1,366.00 |
$185.52 |
| In Buy Zone? |
Yes
|
Yes
|